Superworth

Telomir Pharmaceuticals EPS TELO

Diluted earnings per share by quarter and over the last twelve months, from 2023.

Last 12 months, to Jun 30, 2026
−$0.91
Latest quarter, Q2 FY26
−$0.79
Fiscal year 2025
−$0.33

Telomir Pharmaceuticals' earnings per share was −$0.91 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.79.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.33n/a
FY2024−$0.48n/a
FY2023−$0.48n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.79n/a−$0.91
Q1 FY26−$0.03n/a−$0.29
Q4 FY25−$0.06n/a−$0.33
Q3 FY25−$0.03n/a−$0.37
Q2 FY25−$0.17−440%−$0.54
Q1 FY25−$0.07n/a−$0.32
Q4 FY24−$0.10n/a−$0.48
Q3 FY24−$0.20n/a−$0.72
Q2 FY24$0.05n/a−$0.58
Q1 FY24−$0.23n/a−$0.69
Q4 FY23−$0.34n/a−$0.48
Q3 FY23−$0.06n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Telomir Pharmaceuticals' size, closest first, today.

CompanyEPS, 12 monthsGrowth
TELOTelomir Pharmaceuticals−$0.91
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
ATNMActinium Pharmaceuticals$0.36
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
Peer median$0.52

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Telomir Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.